Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 14

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 14
---
 companies share all costs and future potential profits for GEN1059 on a 50:50 basis. A Phase 1 clinical trial of GEN1059 in solid tumors is recruiting.

#### Second Quarter 2025 Update
• April: Poster presentation at the 2025 Annual Meeting of the American Association for Cancer Research (AACR), “The combination of an EpCAMx4-1BB bispecific antibody with PD-1 blockade exhibits antitumor activity in a murine tumor model unresponsive to each individual antibody.”

GEN1055 (BNT315) – HexaBody-based antibody with potential in solid tumors

• Antibody targeting OX40, created using Genmab’s HexaBody technology platform

• Co-developed in collaboration with BioNTech

GEN1055 (HexaBody-OX40, BNT315), jointly owned by Genmab and BioNTech and created using Genmab’s HexaBody technology platform, is an immune-modulating OX40 agonist antibody designed to promote immunity by enhancing T-cell responses through FcγR-independent OX40 clustering on T cells. GEN1055 is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1055 on a 50:50 basis. Following a strategic evaluation of GEN1055 within the context of Genmab's and BioNTech's portfolios, a decision was made to discontinue the Phase 1/2 clinical trial (NCT06391775) of GEN1055 in malignant solid tumors.

GEN1160 – ADC with potential in both solid tumors and hematological malignancies

• CD70-targeted ADC being evaluated in advanced solid and liquid tumors

• Phase 1/2 clinical trial (NCT05721222) in advanced solid and liquid tumors is recruiting

GEN1160 is a CD70-targeted ADC created using Genmab’s ADC technology. CD70 is a protein expressed on both solid tumors and hematological malignancies. A Phase 1/2 clinical study of GEN1160 in advanced renal cell carcinoma, nasopharyngeal carcinoma and NHL is recruiting.

#### GEN1107 – ADC with potential in solid tumors
• PTK7-targeted ADC being evaluated in advanced solid tumors

• Phase 1/2 clinical trial (NCT06171789) in advanced solid tumors is recruiting

GEN1107 is a PTK7-targeted ADC created using Genmab’s ADC technology.